EP4260852A1 - Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating - Google Patents
Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating Download PDFInfo
- Publication number
- EP4260852A1 EP4260852A1 EP22168549.8A EP22168549A EP4260852A1 EP 4260852 A1 EP4260852 A1 EP 4260852A1 EP 22168549 A EP22168549 A EP 22168549A EP 4260852 A1 EP4260852 A1 EP 4260852A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formulation
- administration
- topical
- hyperhidrosis
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000008454 Hyperhidrosis Diseases 0.000 title claims abstract description 80
- 230000037315 hyperhidrosis Effects 0.000 title claims abstract description 60
- 150000001875 compounds Chemical class 0.000 title claims abstract description 28
- 239000012049 topical pharmaceutical composition Substances 0.000 title claims abstract description 28
- 230000001078 anti-cholinergic effect Effects 0.000 title claims abstract description 26
- 230000035900 sweating Effects 0.000 title claims description 20
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 238000009472 formulation Methods 0.000 claims abstract description 33
- 238000012423 maintenance Methods 0.000 claims abstract description 26
- 238000011200 topical administration Methods 0.000 claims abstract description 9
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 claims description 37
- 229960002462 glycopyrronium bromide Drugs 0.000 claims description 32
- 239000000839 emulsion Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000003995 emulsifying agent Substances 0.000 claims description 16
- SEVCTUCCZYBJER-BSJAROSPSA-N [(3r)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical class C1[N+](CC(=O)OCC)(C)CC[C@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 SEVCTUCCZYBJER-BSJAROSPSA-N 0.000 claims description 10
- FVTWTVQXNAJTQP-UHFFFAOYSA-N diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol Chemical class C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 FVTWTVQXNAJTQP-UHFFFAOYSA-N 0.000 claims description 10
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 8
- 208000004041 Gustatory Sweating Diseases 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- 239000007764 o/w emulsion Substances 0.000 claims description 5
- 229960004258 umeclidinium Drugs 0.000 claims description 5
- 201000001678 Frey syndrome Diseases 0.000 claims description 4
- 230000036617 axillary hyperhidrosis Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- VPNYRYCIDCJBOM-QQTWVUFVSA-M (2R,3S)-glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-QQTWVUFVSA-M 0.000 claims description 2
- VPNYRYCIDCJBOM-POCMBTLOSA-M (2S,3R)-glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CC[C@H]1OC(=O)[C@@](O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-POCMBTLOSA-M 0.000 claims description 2
- 206010059237 Auriculotemporal syndrome Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 206010012645 Diabetic autonomic neuropathy Diseases 0.000 claims description 2
- OFNFMAIFGLDTDC-POCMBTLOSA-M [(3r)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2s)-2-cyclopentyl-2-hydroxy-2-phenylacetate;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1[N+](C)(C)CC[C@H]1OC(=O)[C@@](O)(C=1C=CC=CC=1)C1CCCC1 OFNFMAIFGLDTDC-POCMBTLOSA-M 0.000 claims description 2
- OFNFMAIFGLDTDC-QQTWVUFVSA-M [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 OFNFMAIFGLDTDC-QQTWVUFVSA-M 0.000 claims description 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims 1
- 125000005490 tosylate group Chemical class 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 22
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 21
- -1 GP salts Chemical class 0.000 description 17
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 11
- 229960003511 macrogol Drugs 0.000 description 11
- 230000000699 topical effect Effects 0.000 description 11
- 239000002537 cosmetic Substances 0.000 description 10
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 150000002191 fatty alcohols Chemical class 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 7
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 7
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 6
- 229940082500 cetostearyl alcohol Drugs 0.000 description 6
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 6
- 235000019445 benzyl alcohol Nutrition 0.000 description 5
- 210000004243 sweat Anatomy 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 229960004543 anhydrous citric acid Drugs 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001166 anti-perspirative effect Effects 0.000 description 3
- 239000003213 antiperspirant Substances 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000004013 groin Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 210000001099 axilla Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UJTVNVOGXIDHEY-UHFFFAOYSA-N 2,3-dibromo-2,3-dimethylbutanedinitrile Chemical compound BrC(C(C)(C#N)Br)(C)C#N UJTVNVOGXIDHEY-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003051 Application site pain Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000016495 Horner Syndrome Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028740 Nasal dryness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001445401 Peraxilla Species 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010069714 Ross syndrome Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010069771 Thyroid dermatopathy Diseases 0.000 description 1
- 206010046542 Urinary hesitation Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- UOWOLENSDISMPG-FFUVTKDNSA-M [(3S)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate 4-methylbenzenesulfonate hydrate Chemical class O.Cc1ccc(cc1)S([O-])(=O)=O.C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 UOWOLENSDISMPG-FFUVTKDNSA-M 0.000 description 1
- ANGKOCUUWGHLCE-IEBWSBKVSA-N [(3r)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2s)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@H]1OC(=O)[C@@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-IEBWSBKVSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000003447 amputation stump Anatomy 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004872 foam stabilizing agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000037385 general hyperhidrosis Effects 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 208000000792 harlequin syndrome Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
Definitions
- the present invention relates to a topical formulation comprising at least one anticholinergic compound for use in treating patients suffering from severe hyperhidrosis.
- the present invention relates to the non-therapeutic (cosmetic) use of such a topical formulation for reducing excessive sweating in subjects.
- Hyperhidrosis is a disorder of excessive sweating beyond what is required to maintain normal thermal regulation of the human body. Thus, hyperhidrosis is an extremely inconvenient condition negatively affecting daily life of a person suffering therefrom.
- Hyperhidrosis can be divided into focal and general hyperhidrosis.
- the focal is bilaterally symmetrical: hands, feet, axillae or groins.
- Focal hyperhidrosis from the face/head does occur but is often part of the general form.
- Generalized sweating usually involves both the head and trunk and in severe cases also extremities and groins/glutes. Whereas the majority of patients affected have the primary form which is hereditary, there is also a secondary form, often related to an underlying disease.
- the Hyperhidrosis Disease Severity Scale (HDSS; for details see e.g. Haider A, Solish N. Focal hyperhidrosis: diagnosis and management. CMAJ 2005;172:69-75 ; Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, et al.
- a score of 3 or 4 indicates severe hyperhidrosis.
- a score of 1 and 2 indicates mild and moderate hyperhidrosis, respectively.
- An improvement of 1 HDSS score corresponds to 50% and an improvement of 2 HDSS scores to 80% reduction in sweat production.
- a variety of treatments have been proposed for treating excessive sweating/hyperhidrosis which include aluminum containing antiperspirants, surgical removal of sweat glands and systemic or local treatment with anticholinergic compounds. Any of these treatments, however, entail serious disadvantages.
- Aluminum containing antiperspirants in particular upon continuous use, stain or discolor the textiles coming into contact with the antiperspirant.
- the increasing amount of aluminum in waste water recently has also been increasing environmental concerns.
- removal of the sweat glands means surgery that may be accompanied by at least inconvenient or even serious side effects.
- glycopyrronium salts also named glycopyrrolates; GP salts
- WO 2006/069998 discloses the use of glycopyrronium bromide together with a large variety of other active ingredients for the treatment of excessive sweating.
- WO 2014/134510 relates to a specific glycopyrronium tosylate salt for the treatment of excessive sweating and hyperhidrosis.
- WO 2020/020879 discloses the treatment of patients suffering from only mild/moderate hyperhidrosis (namely with a score of 1 or 2 according to the HDSS).
- compositions basically suffer from at least one insufficiency selected from instability of the composition, inadequate cosmetic acceptance and skin care characteristics, systemic side effects and/or limited efficacy in the treatment of severe hyperhidrosis and/or excessive sweating.
- the object underlying the present invention is the provision of novel methods of improved treatment of severe hyperhidrosis and/or excessive sweating which methods require only a minimum amount of active ingredient while at the same time leading to a maximum efficacy.
- a topical formulation a pharmaceutical composition comprising the same, and the use of the formulation/pharmaceutical composition in treating severe hyperhidrosis, as defined in the claims attached.
- administration i.e. the administration regimen
- a topical formulation to the patient suffering from severe hyperhidrosis particularly into a specific initial phase of administration and a specific maintenance phase of administration
- only a minimum amount of active ingredient is required while nevertheless a maximum efficacy is provided.
- This is particularly important in view of the fact that (primary) hyperhidrosis is a chronic disease that regularly requires a continuous treatment.
- the administration regimen is divided into several distinct phases of administration. These phases basically differ in their frequency of topical application of the formulation to the patient's skin (application or administration per time period) and preferably comprise, even more preferably consist of, an initial phase of administration (also defined herein as initiation phase) and a maintenance phase of administration (also defined herein as continuation or continuous phase).
- the administration starts with the initial phase, followed by the maintenance phase.
- the maintenance phase preferably immediately (directly) follows the initial phase.
- the several phases are also named herein as the respective "time phases” or “time periods” (such as the initial time phase/time period of administration and the maintenance time phase/time period of administration).
- administration of the invention preferably comprises only one initial phase and one maintenance phase over the total treating time of the patient suffering from severe hyperhidrosis.
- the present invention also includes administration with repeatedly interchanging "initial phases” and "maintenance phases” over the total treating time of the patient suffering from severe hyperhidrosis.
- the amount of the topical formulation (and consequently also the amount of the active ingredient, namely the anticholinergic compound) applied per administration remains the same, both in the initial phase and the maintenance phase.
- the amount is also defined as the "predetermined amount” herein.
- the terms “amount” of the topical formulation, “dose” of the topical formulation and “dosage” of the topical formulation are considered identical and used interchangeably. It will be understood by the skilled person that the respective amount also depends on the identity of the anticholinergic compound applied.
- Administration of the topical formulation (also defined herein as administration frequency or application frequency) during the initial phase is from 1 to 4 times a day, more preferably 1 to 2 times a day, more preferably 1 time per day (once-daily), even more preferably 5 to 7 times per week (such as 5, 6, or 7 times per week, e.g. uniformly/evenly distributed or arbitrarily distributed over the week, most preferably uniformly/evenly distributed over the week, namely not more than once daily).
- the total time period (also named duration) of the initial phase is less than six months, preferably two weeks to 4 months, more preferably 3 weeks to 2 months, even more preferably 4-6 weeks, most preferably (around) 4 weeks/one month.
- Administration of the topical formulation (also defined herein as administration frequency or application frequency) during the maintenance phase is from 1 to less than 5 times per week, more preferably 2 to 4 times per week, most preferably 2 to 3 times per week, and particularly preferably 2 times per week. Administration within these periods is either randomly distributed or uniformly distributed, preferably uniformly distributed for compliance reasons. Administration frequency depends on the severity of the hyperhidrosis and can be adapted accordingly.
- the total time period (also named duration) of the maintenance phase is not specifically limited but depends on the severity of the hyperhidrosis to be treated. A minimum duration is several weeks to several months (such as from 4 to 8 weeks to 3 to 8 months). The maximum duration is not particularly limited and ranges from several months to several years. Most preferably the administration according to the invention is a continuous administration over time.
- administration preferably both within the initial phase and the maintenance phase
- the topical formulation is applied in the evening such as prior to bedtime.
- a particularly preferred administration regimen of the topical formulation according to the invention is once daily of a predetermined amount for 4 weeks (initial phase), immediately followed (i.e. starting with week 5) by administration of the same amount 2 to 3 times per week (maintenance phase).
- a "transition phase” between the initial phase and the maintenance phase of 1 to 12 weeks, preferably of 2 to 10 weeks, more preferably 3 to 8 weeks (such as 4, 5, 6, or 7 weeks).
- the administration frequency is step-wise reduced (basically following the patient's efficacy and compliance considerations).
- a particularly preferred reduction is a homogenous (“smooth" and/or “continuous") reduction of administration frequency over the time periods as indicated above.
- the maintenance phase in both cases is then continued for the rest of the hyperhidrosis treatment period.
- the present invention it was surprisingly found that it is possible to reduce the administration frequency of a formulation comprising an anticholinergic compound after a defined initial phase of administration and to continue with the reduced administration frequency with the maintenance phase until the end of the treatment period without losing efficacy. Quite in contrast, it was found out that the treatment of severe hyperhidrosis and/or excessive sweating was highly effective following this administration regimen. This was unexpected because due to the reduced administration frequency the total amount of anticholinergic compound applied was significantly reduced as compared to the prior art treatment with a constant (and constantly high) administration frequency. Importantly the same formulation with the same dose per application was used in the initial phase and in the maintenance phase of administration. Only the frequency of administration was changed.
- High efficacy of the inventive treatment is proven by a reduction and maintenance of the HDSS score by a value of 1 or 2, preferably by 2 (i.e. from HDSS score 3 or 4 to HDSS score 1 or 2).
- a value of 1 or 2 preferably by 2 (i.e. from HDSS score 3 or 4 to HDSS score 1 or 2).
- local and systemic side effects are significantly reduced while a good patient's compliance is achieved.
- the present invention unexpectedly leads to an improved overall performance of the treatment of severe hyperhidrosis and/or excessive sweating.
- the anticholinergic compounds that may be used according to the present invention are not particularly limited, and any anticholinergic compounds may be used.
- Preferred anticholinergic compounds are selected from the group of glycopyrronium (GP) salts, umeclidinium salts, and sofpironium salts, while GP salts are particularly preferred.
- GP salts chemically mean (2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium salts.
- Umeclidinium salts chemically mean salts of diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol.
- Sofpironium salts salts chemically mean salts of [(3R)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate.
- the salts of these compounds that may be used according to the present invention are not particularly limited, and actually any salts may be used. These include the chloride, bromide, fluoride, iodide, nitrate, sulfate, sulfonate, and phosphate salts of glycopyrronium (GP), umeclidinium, and sofpironium, respectively.
- the salts are selected from the group consisting of the bromide, the acetate, and the tosylate salts of glycopyrronium (GP), umeclidinium, and sofpironium, respectively.
- the salts are selected from the group consisting of the bromide, the acetate, and the tosylate salts of glycopyrronium (GP).
- the emulsion of the invention may contain one, two, three or more different salts of glycopyrronium (GP), umeclidinium, and sofpironium, respectively. However, preferably it contains only one salt, more preferably only one GP salt, such as the bromide, the acetate, and the tosylate salts of glycopyrronium (GP).
- the anticholinergic compound is GP bromide.
- the glycopyrronium (GP) salts and sofpironium salts of the present invention include the racemic mixtures thereof (umeclidinium salts are free of any chiral center).
- the GP salt according to the present invention may be a racemic mixture of the (3 R )-3-[(2 S )-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium and (3S)-3-[(2 R )-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium salts.
- the sofpironium salts used according to the present invention are those defined in WO 2014/144075 A1 .
- the formulation according to the present invention may contain the anticholinergic compound, and in particular the GP salt such as the bromide (GPB), in an amount of 0.05 to 5 wt.%, preferably of 0.1 to 3 wt.%, more preferably of 0.2 to 2 wt.%, and even more preferably of 0.5 to 1.5 wt.%, based on the weight of the total formulation.
- the GP salt such as the bromide (GPB)
- the anticholinergic compound and in particular the GP salt such as the bromide (GPB)
- GPB GP salt
- a high efficacy in reducing excessive sweating is achieved in patients suffering from severe hyperhidrosis rated as 3 or 4, preferably as 4, in the Hyperhidrosis Disease Severity Scale (HDSS), while at the same time potential undesirable side effects of GP salts can be avoided.
- a stable formulation can be obtained even with high amounts of GP salt (namely even with 2 to 5 wt.% and in particular with 2 to 3 wt.%).
- an amount of about 1.0 wt.% GP salt is most preferred especially from a cost, efficacy and side effect (safety) perspective.
- the topical formulation containing GPB (e.g. as a 0.5 to 2.0 wt.%, most preferred as a 1.0 wt.% formulation, based on the weight of the total formulation) is preferably administered in an amount within a range of from 200 to 800 mg, preferably from 400 to 600 mg, most preferably 500 to 550 mg (such as 540 mg) per application. In a most preferred embodiment the formulation is administered in an amount of 540 mg per application per axilla.
- the formulation of the present invention may be in any form that allows the topical application onto the skin of a mammal.
- This includes, without being limited thereto, an emulsion (such as a W/O, O/W, W/O/W, O/W/O emulsion), a gel, a solution, and a mixed form of a gel and an emulsion (emulgel).
- the formulation is an emulsion.
- a topical emulsion may be either a water-in-oil emulsion (also named W/O emulsion) or an oil-in-water emulsion (also named O/W emulsion).
- the topical emulsion of the present invention is an oil-in-water emulsion (O/W emulsion) comprising one or more anticholinergic compound(s) as active ingredient, wherein the emulsion contains a disperse (inner) oil phase, a continuous (outer) water phase containing the anticholinergic compound, and an emulsifier.
- the anticholinergic compound due to its hydrophilic property and its water solubility is mainly contained in the water phase itself and in particular at the interface of the water and oil phases of the emulsion.
- the oil phase of the topical emulsion of the present invention may be a typical oil phase of emulsions known in the prior art.
- Preferred as the main (basic) oil ingredient of the oil phase are linear or branched long chain fatty alcohols having 6 to 36 carbon atoms, preferably having 6 to 22 carbon atoms.
- the oil phase contains octyldodecanol because of its skin smoothening and moisturizing effects and stability against oxidation even under acidic conditions (e.g. pH 4). Octyldodecanol further improves the permeation behaviour of the emulsion of the present invention.
- the oil phase containing octyldodecanol is preferred because it provides improved skin care (e.g. smoothening and moisturizing) effects corresponding to an improved cosmetic acceptance of the patient or user.
- the water phase comprises mainly water as solvent and the anticholinergic compound as active ingredient for treating hyperhidrosis.
- the water phase may also comprise water soluble/miscible compounds (e.g. lower alcohols such as ethanol or isopropanol), preservatives (such as benzyl alcohol or phenoxyethanol), pH adjusting agents or buffers (such as citric acid/citrate), as well as moisturizing agents (such as propylene glycol) and other typical hydrophilic pharmaceutical/cosmetic excipients.
- water soluble/miscible compounds e.g. lower alcohols such as ethanol or isopropanol
- preservatives such as benzyl alcohol or phenoxyethanol
- pH adjusting agents or buffers such as citric acid/citrate
- moisturizing agents such as propylene glycol
- the topical emulsions, and preferably the O/W emulsions, of the present invention contain a smaller oil phase as compared to the water phase.
- the oil phase ranges from 10 to 25 %
- the water phase ranges from 65 to 80 wt.% of the total weight of the emulsion.
- the emulsion of the invention surprisingly provides both for better stability (no phase separation) and for improved skin care characteristics, as already mentioned above.
- the release rate of anticholinergic compounds from the larger water phase was increased.
- the opposite was expected, namely a decreased release rate due to the larger water phase and the high water solubility and hydrophilic properties of the anticholinergic compounds. This allows for further reducing the amount of the anticholinergic compound leading to a better side effect profile without reducing efficacy.
- the emulsifier of the topical emulsion may be any emulsifier suitable to provide for a W/O or O/W emulsion.
- the emulsifier provides for an O/W emulsion.
- a particularly preferred emulsifier according to the present invention is an emulsifier system that contains at least three different components, namely at least one macrogol glycerol fatty acid ester, at least one glycerol fatty acid ester, and at least one fatty alcohol.
- macrogol as common in the pharmaceutical field, is used as a synonym for "polyethylene glycol (PEG)".
- PEG polyethylene glycol
- the emulsifier system comprises a combination of a macrogol glycerol fatty acid ester, a glycerol fatty acid ester, and a fatty alcohol.
- the fatty alcohol it is preferred to use a mixture of two fatty alcohols.
- the above mentioned effects i.e. efficacy with patients suffering from severe hyperhidrosis rated as 3 or 4 in the Hyperhidrosis Disease Severity Scale (HDSS), improved side effect profile, improved compliance and cosmetic acceptance/skin care characteristics also including improved stability, increased release rate
- HDSS Hyperhidrosis Disease Severity Scale
- the emulsifier system comprises a combination of macrogol glycerol monostearate, glycerol monostearate, and a mixture of cetyl alcohol and stearyl alcohol (e.g. with minimum 40.0 wt.% stearyl alcohol). Even more preferably, the emulsifier system comprises a combination of macrogol 20 glycerol monostearate, glycerol monostearate 40-55, and cetostearyl alcohol. Cetostearyl alcohol is a mixture of fatty acid alcohols, in particular a mixture of cetyl and stearyl alcohols. Most preferably the emulsifier system (essentially) consists of these indicated combinations.
- the topical (O/W) emulsion according to the present invention may contain the respective components of the emulsifier system in the following amounts: 4.0 to 10.0 wt.%, preferably of 5.0 to 9.0 wt.%, more preferably of 6.0 to 8.0 wt.%, and even more preferably of 6.5 to 7.5 wt.% of the macrogol glycerol fatty acid ester; 1.5 to 7.5 wt.%, preferably of 2.5 to 6.5 wt.%, more preferably of 3.5 to 5.5 wt.%, and even more preferably of 4.0 to 5.0 wt.% of glycerol fatty acid ester; 5.0 to 11.0 wt.%, preferably of 6.0 to 10.0 wt.%, more preferably of 7.0 to 9.0 wt.%, and even more preferably of 7.5 to 8.5 wt.% of fatty alcohol, based on the weight of the total emulsion, respectively.
- the emulsifier system of the topical (W/O) emulsion according to the present invention may contain the respective components in the following ratios: 21 to 51 wt.%, preferably of 26 to 46 wt.%, more preferably of 31 to 41 wt.%, and even more preferably of 33 to 38 wt.% of macrogol glycerol fatty acid ester; 8 to 38 wt.%, preferably of 13 to 33 wt.%, more preferably of 18 to 28 wt.%, and even more preferably of 21 to 26 wt.% of glycerol fatty acid ester; 26 to 56 wt.%, preferably of 31 to 51 wt.%, more preferably of 36 to 46 wt.%, and even more preferably of 38 to 44 wt.% of fatty alcohol (or fatty alcohol mixture), based on the weight of the emulsifier system, respectively.
- 21 to 51 wt.% preferably of 26 to 46 wt.%
- the topical formulation of the present invention can be used as a pharmaceutical composition/medicament or as a cosmetic composition, depending on the indication to be treated and the respective regulatory requirements.
- the formulations/compositions in accordance with the present invention may contain cosmetically and pharmaceutically/dermatologically acceptable excipients known to the skilled person. These include, next to the ones already mentioned above, for example further solvents such as organic solvents, gelling agents, buffers, detergents, emulsifiers, solubilizers, humectants, fillers, bioadhesives, emollients, preservatives, bactericides, surfactants, perfumes, thickeners, softening agents, moisturizing agents, oils, fats, waxes, water, alcohols, polyols, polymers, foam stabilizers, foaming agents, anti-foaming agents, or other suitable components of a pharmaceutical or cosmetic preparation.
- solvents such as organic solvents, gelling agents, buffers, detergents, emulsifiers, solubilizers, humectants, fillers, bioadhesives, emollients, preservatives, bactericides
- bactericides examples are organic acids like formic acid, sorbic acid and benzoic acid.
- esters of p-hydroxybenzoic acid, formaldehyde-releasing agents like DMDM hydantoin, imidazolidinylurea or methyl chloroisothiazolinone, methylisothiazolinone, dibromodicyanobutane, iodopropynyl butylcarbamte, phenoxyethanol or benzyl alcohol can be used as bactericides.
- pharmaceutically/dermatologically acceptable excipients according to the present invention may be inorganic or organic substances for topical administration.
- the pH value of the formulation can be stabilized using buffer systems consisting of polyacids and their salts. Examples for such polyacids are citric acid, tartaric acid and malic acid.
- the formulation is preferably a dermatological composition suitable to be applied topically on the skin of a mammal.
- the form of the composition is not particularly limited.
- the compositions are emulsions preferably in the form of lotions, creams, sprays, shampoos, foams, or saturated pads, wipes or cloth.
- a dispenser is disclosed in WO 2020/208063 that is designed to dispense fixed and constant dosages of formulation (per pump actuation).
- Patients to be treated according to the present invention are defined as patients suffering from severe hyperhidrosis rated as 3 or 4, preferably as 4, in the Hyperhidrosis Disease Severity Scale (HDSS).
- HDSS Hyperhidrosis Disease Severity Scale
- Next to HDSS there are alternative definitions existing in the prior art to define severe hyperhidrosis. These are included in the present invention as well.
- "Severe Hyperhidrosis” herein is intended to comprise all clinical disorders/indications associated with excessive sweating, in particular primary axillary hyperhidrosis. These hyperhidrosis disorders may include severe forms of primary and secondary hyperhidrosis, gustatory sweating associated with Frey's syndrome, gustatory sweating associated with diabetic autonomic neuropathy, and excessive sweating in general.
- the following indications can be treated according to the present invention and are associated with dermatology, e.g. eccrine nevus, idiopathic unilateral focal hyperhidrosis, vascular deformities, pretibial myxedema; associated with gynaecology, e.g. postmenopausal hyperhidrosis; iatrogenic, such as associated with medicines, namely methadone or other opiates, cholinergics such as galantamine, SSRIs; associated with infection, e.g. brucellosis, HIV, chronic malaria, TBC, endocarditis; associated with surgery e.g.
- dermatology e.g. eccrine nevus, idiopathic unilateral focal hyperhidrosis, vascular deformities, pretibial myxedema
- gynaecology e.g. postmenopausal hyperhidrosis
- iatrogenic such as associated with medicines, namely methadone or other
- compensatory hyperhidrosis after sympathectomy associated with medicines, such diabetes (hyperhidrosis due to neuropathy or hypoglycaemia), endocrine diseases (acromegaly, pheochromocytoma, hyperthyroidism, hypogonadism, insulinoma, heart failure, obesity); associated with neurology, e.g. central or peripheral lesion, Harlequin syndrome, Horner's syndrome, compensatory hyperhidrosis, Ross syndrome, Parkinson's disease, polyneuropathies; associated with oncology, such as carcinoid, lymphoma, with several malignancies; associated with orthopaedics, e.g. hyperhidrosis from amputation stump; associated with psychiatry, e.g.
- Non-therapeutic (cosmetic) use of the topical formulation of the present invention includes the topical application of the formulation on the skin of a mammal in individuals experiencing excessive sweating rated as (or at least comparable with the state of) 3 or 4, preferably as 4, in the Hyperhidrosis Disease Severity Scale (HDSS).
- HDSS Hyperhidrosis Disease Severity Scale
- the formulation of the present invention is applied topically on the skin of a mammal.
- Typical application sites include the face (e.g. forehead, chin, neck and scalp), armpit (axilla), underarms, palms of the hands, soles of the feet, backs of the knees, trunk, and groin.
- a particularly preferable application site according to the invention is the armpit (axilla).
- the following examples have been prepared by combining the indicated ingredients using a conventional mixer (e.g. Becomix RW 320). All ingredients are commercially available.
- Macrogol 20 glycerol monostearate is also known as polyethylene glycol (PEG)-20 glyceryl stearate.
- Glycerol monostearate 40-55 is also known as glycerol monostearate 40-55% (Type II).
- Cetostearyl alcohol is a mixture of cetyl and stearyl alcohols.
- Formulations according to the present invention were tested in a clinical trial assessing pharmacokinetics, local and systemic tolerability and local efficacy of glycopyrronium bromide (GPB) in a topical formulation in a placebo controlled, double blind study in subjects with severe axillary hyperhidrosis. 517 patients with primary axillary hyperhidrosis were enrolled in the study. According to the present invention only patients suffering from severe hyperhidrosis rated as 3 or 4 in the Hyperhidrosis Disease Severity Scale (HDSS) and at least 50 mg of sweat production over a period of 5 minutes were evaluated.
- HDSS Hyperhidrosis Disease Severity Scale
- the patients applied a predetermined dose of the cream 540 mg cream, corresponding to 4.4 mg glycopyrronium
- the frequency of application was reduced to (in average) 3 times per week (maintenance phase).
- the treatment success was maintained with the lower frequency of product administration of the maintenance phase.
- Treatment success is shown by means of reduction in HDSS and gravimetric measurement of absolute sweat reduction.
- other parameters to define success of treatment include but are not limited to other quality of life measurement tools such as DLQI, HidroQoL, Skindex-16 etc., or other means of objective sweat measurement such as minor tests, size of sweat stains etc.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
Abstract
The present invention relates to a topical formulation comprising at least one anticholinergic compound for use in treating patients suffering from severe hyperhidrosis, wherein administration of the formulation to the patient comprises:
a) an initial phase with a topical administration of a predetermined amount of the formulation 5 to 7 times per week for a total time period of less than six months; followed by
b) a maintenance phase with a topical administration of the same amount of the formulation 1 to less than 5 times per week.
a) an initial phase with a topical administration of a predetermined amount of the formulation 5 to 7 times per week for a total time period of less than six months; followed by
b) a maintenance phase with a topical administration of the same amount of the formulation 1 to less than 5 times per week.
Description
- The present invention relates to a topical formulation comprising at least one anticholinergic compound for use in treating patients suffering from severe hyperhidrosis. In addition the present invention relates to the non-therapeutic (cosmetic) use of such a topical formulation for reducing excessive sweating in subjects.
- Hyperhidrosis is a disorder of excessive sweating beyond what is required to maintain normal thermal regulation of the human body. Thus, hyperhidrosis is an extremely inconvenient condition negatively affecting daily life of a person suffering therefrom. Hyperhidrosis can be divided into focal and general hyperhidrosis. The focal is bilaterally symmetrical: hands, feet, axillae or groins. Focal hyperhidrosis from the face/head does occur but is often part of the general form. Generalized sweating usually involves both the head and trunk and in severe cases also extremities and groins/glutes. Whereas the majority of patients affected have the primary form which is hereditary, there is also a secondary form, often related to an underlying disease.
- The Hyperhidrosis Disease Severity Scale (HDSS; for details see e.g. Haider A, Solish N. Focal hyperhidrosis: diagnosis and management. CMAJ 2005;172:69-75; Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg 2007;33(8):908-23) is a 4-point scale designed to assess the severity of hyperhidrosis in everyday clinical practice and effectiveness of hyperhidrosis treatment. It is a disease-specific diagnostic tool that provides a highly reliable qualitative measure of the severity of the patient's condition based on how it affects daily activities. A score of 3 or 4 indicates severe hyperhidrosis. A score of 1 and 2 indicates mild and moderate hyperhidrosis, respectively. An improvement of 1 HDSS score corresponds to 50% and an improvement of 2 HDSS scores to 80% reduction in sweat production.
- A variety of treatments have been proposed for treating excessive sweating/hyperhidrosis which include aluminum containing antiperspirants, surgical removal of sweat glands and systemic or local treatment with anticholinergic compounds. Any of these treatments, however, entail serious disadvantages. Aluminum containing antiperspirants, in particular upon continuous use, stain or discolor the textiles coming into contact with the antiperspirant. In addition, the increasing amount of aluminum in waste water recently has also been increasing environmental concerns. On the other hand, removal of the sweat glands means surgery that may be accompanied by at least inconvenient or even serious side effects.
- As an alternative to the treatments mentioned above, anticholinergic compounds such as glycopyrronium salts (also named glycopyrrolates; GP salts) have been proposed for the treatment of excessive sweating and hyperhidrosis.
WO 2006/069998 discloses the use of glycopyrronium bromide together with a large variety of other active ingredients for the treatment of excessive sweating.WO 2014/134510 relates to a specific glycopyrronium tosylate salt for the treatment of excessive sweating and hyperhidrosis.WO 2020/020879 discloses the treatment of patients suffering from only mild/moderate hyperhidrosis (namely with a score of 1 or 2 according to the HDSS). - However, all of these known compositions basically suffer from at least one insufficiency selected from instability of the composition, inadequate cosmetic acceptance and skin care characteristics, systemic side effects and/or limited efficacy in the treatment of severe hyperhidrosis and/or excessive sweating.
- In view thereof there is still need in the prior art for improved methods of treating severe hyperhidrosis and/or excessive sweating.
- Therefore, the object underlying the present invention is the provision of novel methods of improved treatment of severe hyperhidrosis and/or excessive sweating which methods require only a minimum amount of active ingredient while at the same time leading to a maximum efficacy.
- This object is achieved by a topical formulation, a pharmaceutical composition comprising the same, and the use of the formulation/pharmaceutical composition in treating severe hyperhidrosis, as defined in the claims attached. In particular, it was surprisingly found out that by dividing administration (i.e. the administration regimen) of a topical formulation to the patient suffering from severe hyperhidrosis particularly into a specific initial phase of administration and a specific maintenance phase of administration, only a minimum amount of active ingredient is required while nevertheless a maximum efficacy is provided. This is particularly important in view of the fact that (primary) hyperhidrosis is a chronic disease that regularly requires a continuous treatment. At the same time it was surprisingly found that local and systemic side effects (such as skin irritation or even inflammation at application site, application site pain, dry mouth, dry skin, dry eye, blurred vision, mydriasis, constipation, urinary hesitation, urinary retention, and nasal dryness, known from e.g. glycopyrronium salts containing compositions) are significantly reduced while the patient's compliance is not affected. In the prior art it was not possible to sufficiently fulfill these properties all together at the same time.
- According to the present invention the administration regimen is divided into several distinct phases of administration. These phases basically differ in their frequency of topical application of the formulation to the patient's skin (application or administration per time period) and preferably comprise, even more preferably consist of, an initial phase of administration (also defined herein as initiation phase) and a maintenance phase of administration (also defined herein as continuation or continuous phase). The administration starts with the initial phase, followed by the maintenance phase. The maintenance phase preferably immediately (directly) follows the initial phase. Alternatively, there may be a "transition phase" during which the administration regime of the initial phase is step-wise reduced to achieve the administration regime of the maintenance phase. This helps the patients to carefully adapt the administration according to the invention while maximizing compliance and efficacy. The several phases are also named herein as the respective "time phases" or "time periods" (such as the initial time phase/time period of administration and the maintenance time phase/time period of administration). While not being limited thereto, administration of the invention preferably comprises only one initial phase and one maintenance phase over the total treating time of the patient suffering from severe hyperhidrosis. However, it is also included within the invention to return from the administration frequency of the maintenance phase back to the administration frequency of the initial phase and again back to the administration frequency of the maintenance phase, in case efficacy considerations of the treatment require. In other words, the present invention also includes administration with repeatedly interchanging "initial phases" and "maintenance phases" over the total treating time of the patient suffering from severe hyperhidrosis.
- According to the invention the amount of the topical formulation (and consequently also the amount of the active ingredient, namely the anticholinergic compound) applied per administration remains the same, both in the initial phase and the maintenance phase. The amount is also defined as the "predetermined amount" herein. In this respect the terms "amount" of the topical formulation, "dose" of the topical formulation and "dosage" of the topical formulation are considered identical and used interchangeably. It will be understood by the skilled person that the respective amount also depends on the identity of the anticholinergic compound applied.
- Administration of the topical formulation (also defined herein as administration frequency or application frequency) during the initial phase is from 1 to 4 times a day, more preferably 1 to 2 times a day, more preferably 1 time per day (once-daily), even more preferably 5 to 7 times per week (such as 5, 6, or 7 times per week, e.g. uniformly/evenly distributed or arbitrarily distributed over the week, most preferably uniformly/evenly distributed over the week, namely not more than once daily). The total time period (also named duration) of the initial phase is less than six months, preferably two weeks to 4 months, more preferably 3 weeks to 2 months, even more preferably 4-6 weeks, most preferably (around) 4 weeks/one month.
- Administration of the topical formulation (also defined herein as administration frequency or application frequency) during the maintenance phase is from 1 to less than 5 times per week, more preferably 2 to 4 times per week, most preferably 2 to 3 times per week, and particularly preferably 2 times per week. Administration within these periods is either randomly distributed or uniformly distributed, preferably uniformly distributed for compliance reasons. Administration frequency depends on the severity of the hyperhidrosis and can be adapted accordingly. The total time period (also named duration) of the maintenance phase is not specifically limited but depends on the severity of the hyperhidrosis to be treated. A minimum duration is several weeks to several months (such as from 4 to 8 weeks to 3 to 8 months). The maximum duration is not particularly limited and ranges from several months to several years. Most preferably the administration according to the invention is a continuous administration over time.
- According to the invention administration (preferably both within the initial phase and the maintenance phase) the topical formulation is applied in the evening such as prior to bedtime.
- A particularly preferred administration regimen of the topical formulation according to the invention is once daily of a predetermined amount for 4 weeks (initial phase), immediately followed (i.e. starting with week 5) by administration of the same amount 2 to 3 times per week (maintenance phase). Alternatively, there is a "transition phase" between the initial phase and the maintenance phase of 1 to 12 weeks, preferably of 2 to 10 weeks, more preferably 3 to 8 weeks (such as 4, 5, 6, or 7 weeks). During this "transition phase" the administration frequency is step-wise reduced (basically following the patient's efficacy and compliance considerations). A particularly preferred reduction is a homogenous ("smooth" and/or "continuous") reduction of administration frequency over the time periods as indicated above. The maintenance phase in both cases is then continued for the rest of the hyperhidrosis treatment period.
- According to the present invention it was surprisingly found that it is possible to reduce the administration frequency of a formulation comprising an anticholinergic compound after a defined initial phase of administration and to continue with the reduced administration frequency with the maintenance phase until the end of the treatment period without losing efficacy. Quite in contrast, it was found out that the treatment of severe hyperhidrosis and/or excessive sweating was highly effective following this administration regimen. This was unexpected because due to the reduced administration frequency the total amount of anticholinergic compound applied was significantly reduced as compared to the prior art treatment with a constant (and constantly high) administration frequency. Importantly the same formulation with the same dose per application was used in the initial phase and in the maintenance phase of administration. Only the frequency of administration was changed. High efficacy of the inventive treatment is proven by a reduction and maintenance of the HDSS score by a value of 1 or 2, preferably by 2 (i.e. from HDSS score 3 or 4 to HDSS score 1 or 2). At the same time it was surprisingly found that local and systemic side effects are significantly reduced while a good patient's compliance is achieved. It was particularly unexpected to keep the high efficacy with a reduced administration regimen even with patients suffering from severe hyperhidrosis and/or excessive sweating. In conclusion, the present invention unexpectedly leads to an improved overall performance of the treatment of severe hyperhidrosis and/or excessive sweating.
- The anticholinergic compounds that may be used according to the present invention are not particularly limited, and any anticholinergic compounds may be used. Preferred anticholinergic compounds are selected from the group of glycopyrronium (GP) salts, umeclidinium salts, and sofpironium salts, while GP salts are particularly preferred. GP salts chemically mean (2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium salts. Umeclidinium salts chemically mean salts of diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol. Sofpironium salts salts chemically mean salts of [(3R)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate. The salts of these compounds that may be used according to the present invention are not particularly limited, and actually any salts may be used. These include the chloride, bromide, fluoride, iodide, nitrate, sulfate, sulfonate, and phosphate salts of glycopyrronium (GP), umeclidinium, and sofpironium, respectively. Also suitable are the acetate, propionate, glycolate, pyruvate, oxalate, succinate, fumarate, tartrate, citrate, benzoate, methanesulfonate, 4-methylbenzenesulfonate (tosylate), and salicylate salts of glycopyrronium (GP), umeclidinium, and sofpironium, respectively. Particularly preferably the salts are selected from the group consisting of the bromide, the acetate, and the tosylate salts of glycopyrronium (GP), umeclidinium, and sofpironium, respectively. Most preferably the salts are selected from the group consisting of the bromide, the acetate, and the tosylate salts of glycopyrronium (GP). The emulsion of the invention may contain one, two, three or more different salts of glycopyrronium (GP), umeclidinium, and sofpironium, respectively. However, preferably it contains only one salt, more preferably only one GP salt, such as the bromide, the acetate, and the tosylate salts of glycopyrronium (GP). Most preferably the anticholinergic compound is GP bromide.
- The glycopyrronium (GP) salts and sofpironium salts of the present invention include the racemic mixtures thereof (umeclidinium salts are free of any chiral center). For example, the GP salt according to the present invention may be a racemic mixture of the (3R)-3-[(2S)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium and (3S)-3-[(2R)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium salts. Preferably a racemic mixture of (3R)-3-[(2S)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide and (3S)-3-[(2R)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide or a racemic mixture of (3R)-3-[(2S)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium tosylate and (3S)-3-[(2R)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium tosylate is used. The sofpironium salts used according to the present invention are those defined in
WO 2014/144075 A1 . - The formulation according to the present invention may contain the anticholinergic compound, and in particular the GP salt such as the bromide (GPB), in an amount of 0.05 to 5 wt.%, preferably of 0.1 to 3 wt.%, more preferably of 0.2 to 2 wt.%, and even more preferably of 0.5 to 1.5 wt.%, based on the weight of the total formulation. When the anticholinergic compound, and in particular the GP salt such as the bromide (GPB), is contained in an amount within these ranges a high efficacy in reducing excessive sweating is achieved in patients suffering from severe hyperhidrosis rated as 3 or 4, preferably as 4, in the Hyperhidrosis Disease Severity Scale (HDSS), while at the same time potential undesirable side effects of GP salts can be avoided. Furthermore, surprisingly a stable formulation can be obtained even with high amounts of GP salt (namely even with 2 to 5 wt.% and in particular with 2 to 3 wt.%). Overall, an amount of about 1.0 wt.% GP salt (in particular GPB or GP tosylate, most preferably GPB) is most preferred especially from a cost, efficacy and side effect (safety) perspective.
- The topical formulation containing GPB (e.g. as a 0.5 to 2.0 wt.%, most preferred as a 1.0 wt.% formulation, based on the weight of the total formulation) is preferably administered in an amount within a range of from 200 to 800 mg, preferably from 400 to 600 mg, most preferably 500 to 550 mg (such as 540 mg) per application. In a most preferred embodiment the formulation is administered in an amount of 540 mg per application per axilla.
- The formulation of the present invention may be in any form that allows the topical application onto the skin of a mammal. This includes, without being limited thereto, an emulsion (such as a W/O, O/W, W/O/W, O/W/O emulsion), a gel, a solution, and a mixed form of a gel and an emulsion (emulgel). Preferably the formulation is an emulsion.
- According to the present invention a topical emulsion may be either a water-in-oil emulsion (also named W/O emulsion) or an oil-in-water emulsion (also named O/W emulsion). In a preferred embodiment the topical emulsion of the present invention is an oil-in-water emulsion (O/W emulsion) comprising one or more anticholinergic compound(s) as active ingredient, wherein the emulsion contains a disperse (inner) oil phase, a continuous (outer) water phase containing the anticholinergic compound, and an emulsifier. Namely, the anticholinergic compound due to its hydrophilic property and its water solubility is mainly contained in the water phase itself and in particular at the interface of the water and oil phases of the emulsion.
- The oil phase of the topical emulsion of the present invention, and preferably of the O/W emulsion, may be a typical oil phase of emulsions known in the prior art. Preferred as the main (basic) oil ingredient of the oil phase, however, are linear or branched long chain fatty alcohols having 6 to 36 carbon atoms, preferably having 6 to 22 carbon atoms. More preferably according to the present invention the oil phase contains octyldodecanol because of its skin smoothening and moisturizing effects and stability against oxidation even under acidic conditions (e.g. pH 4). Octyldodecanol further improves the permeation behaviour of the emulsion of the present invention. Thus, the oil phase containing octyldodecanol is preferred because it provides improved skin care (e.g. smoothening and moisturizing) effects corresponding to an improved cosmetic acceptance of the patient or user.
- The water phase comprises mainly water as solvent and the anticholinergic compound as active ingredient for treating hyperhidrosis. The water phase may also comprise water soluble/miscible compounds (e.g. lower alcohols such as ethanol or isopropanol), preservatives (such as benzyl alcohol or phenoxyethanol), pH adjusting agents or buffers (such as citric acid/citrate), as well as moisturizing agents (such as propylene glycol) and other typical hydrophilic pharmaceutical/cosmetic excipients. However, it is preferred not to incorporate glycerol itself into the emulsion of the invention because glycerol has been shown to provide a detrimental effect on stability of the emulsion.
- The topical emulsions, and preferably the O/W emulsions, of the present invention contain a smaller oil phase as compared to the water phase. Preferably the oil phase ranges from 10 to 25 %, and the water phase ranges from 65 to 80 wt.% of the total weight of the emulsion. Despite of the relatively small ratio of the oil phase the emulsion of the invention surprisingly provides both for better stability (no phase separation) and for improved skin care characteristics, as already mentioned above. At the same time it was unexpected that the release rate of anticholinergic compounds from the larger water phase was increased. Actually, the opposite was expected, namely a decreased release rate due to the larger water phase and the high water solubility and hydrophilic properties of the anticholinergic compounds. This allows for further reducing the amount of the anticholinergic compound leading to a better side effect profile without reducing efficacy.
- The emulsifier of the topical emulsion may be any emulsifier suitable to provide for a W/O or O/W emulsion. Preferably the emulsifier provides for an O/W emulsion.
- A particularly preferred emulsifier according to the present invention is an emulsifier system that contains at least three different components, namely at least one macrogol glycerol fatty acid ester, at least one glycerol fatty acid ester, and at least one fatty alcohol. In the present application the term "macrogol", as common in the pharmaceutical field, is used as a synonym for "polyethylene glycol (PEG)". This is also supported by the skilled person's common general knowledge. Preferably, the emulsifier system comprises a combination of a macrogol glycerol fatty acid ester, a glycerol fatty acid ester, and a fatty alcohol. As the fatty alcohol it is preferred to use a mixture of two fatty alcohols. By using the specific emulsifier system in the topical (O/W) emulsion of the present invention the above mentioned effects (i.e. efficacy with patients suffering from severe hyperhidrosis rated as 3 or 4 in the Hyperhidrosis Disease Severity Scale (HDSS), improved side effect profile, improved compliance and cosmetic acceptance/skin care characteristics also including improved stability, increased release rate) can be achieved.
- More preferably with respect to the above described effects, the emulsifier system comprises a combination of macrogol glycerol monostearate, glycerol monostearate, and a mixture of cetyl alcohol and stearyl alcohol (e.g. with minimum 40.0 wt.% stearyl alcohol). Even more preferably, the emulsifier system comprises a combination of macrogol 20 glycerol monostearate, glycerol monostearate 40-55, and cetostearyl alcohol. Cetostearyl alcohol is a mixture of fatty acid alcohols, in particular a mixture of cetyl and stearyl alcohols. Most preferably the emulsifier system (essentially) consists of these indicated combinations.
- The topical (O/W) emulsion according to the present invention may contain the respective components of the emulsifier system in the following amounts: 4.0 to 10.0 wt.%, preferably of 5.0 to 9.0 wt.%, more preferably of 6.0 to 8.0 wt.%, and even more preferably of 6.5 to 7.5 wt.% of the macrogol glycerol fatty acid ester; 1.5 to 7.5 wt.%, preferably of 2.5 to 6.5 wt.%, more preferably of 3.5 to 5.5 wt.%, and even more preferably of 4.0 to 5.0 wt.% of glycerol fatty acid ester; 5.0 to 11.0 wt.%, preferably of 6.0 to 10.0 wt.%, more preferably of 7.0 to 9.0 wt.%, and even more preferably of 7.5 to 8.5 wt.% of fatty alcohol, based on the weight of the total emulsion, respectively. By applying these preferred ranges the stability, cosmetic acceptance and efficacy is further improved.
- The emulsifier system of the topical (W/O) emulsion according to the present invention may contain the respective components in the following ratios: 21 to 51 wt.%, preferably of 26 to 46 wt.%, more preferably of 31 to 41 wt.%, and even more preferably of 33 to 38 wt.% of macrogol glycerol fatty acid ester; 8 to 38 wt.%, preferably of 13 to 33 wt.%, more preferably of 18 to 28 wt.%, and even more preferably of 21 to 26 wt.% of glycerol fatty acid ester; 26 to 56 wt.%, preferably of 31 to 51 wt.%, more preferably of 36 to 46 wt.%, and even more preferably of 38 to 44 wt.% of fatty alcohol (or fatty alcohol mixture), based on the weight of the emulsifier system, respectively. By applying these preferred ratios the stability, cosmetic acceptance and efficacy is further improved.
- The topical formulation of the present invention can be used as a pharmaceutical composition/medicament or as a cosmetic composition, depending on the indication to be treated and the respective regulatory requirements.
- The formulations/compositions in accordance with the present invention may contain cosmetically and pharmaceutically/dermatologically acceptable excipients known to the skilled person. These include, next to the ones already mentioned above, for example further solvents such as organic solvents, gelling agents, buffers, detergents, emulsifiers, solubilizers, humectants, fillers, bioadhesives, emollients, preservatives, bactericides, surfactants, perfumes, thickeners, softening agents, moisturizing agents, oils, fats, waxes, water, alcohols, polyols, polymers, foam stabilizers, foaming agents, anti-foaming agents, or other suitable components of a pharmaceutical or cosmetic preparation.
- Examples for bactericides are organic acids like formic acid, sorbic acid and benzoic acid. In addition esters of p-hydroxybenzoic acid, formaldehyde-releasing agents like DMDM hydantoin, imidazolidinylurea or methyl chloroisothiazolinone, methylisothiazolinone, dibromodicyanobutane, iodopropynyl butylcarbamte, phenoxyethanol or benzyl alcohol can be used as bactericides.
- Further, pharmaceutically/dermatologically acceptable excipients according to the present invention may be inorganic or organic substances for topical administration. The pH value of the formulation can be stabilized using buffer systems consisting of polyacids and their salts. Examples for such polyacids are citric acid, tartaric acid and malic acid.
- In the present invention, the formulation is preferably a dermatological composition suitable to be applied topically on the skin of a mammal. The form of the composition is not particularly limited. In preferred embodiments, the compositions are emulsions preferably in the form of lotions, creams, sprays, shampoos, foams, or saturated pads, wipes or cloth. Preferably they can be applied using a dispenser. A particularly suitable dispenser is disclosed in
WO 2020/208063 that is designed to dispense fixed and constant dosages of formulation (per pump actuation). - Patients to be treated according to the present invention are defined as patients suffering from severe hyperhidrosis rated as 3 or 4, preferably as 4, in the Hyperhidrosis Disease Severity Scale (HDSS). Next to HDSS there are alternative definitions existing in the prior art to define severe hyperhidrosis. These are included in the present invention as well. "Severe Hyperhidrosis" herein is intended to comprise all clinical disorders/indications associated with excessive sweating, in particular primary axillary hyperhidrosis. These hyperhidrosis disorders may include severe forms of primary and secondary hyperhidrosis, gustatory sweating associated with Frey's syndrome, gustatory sweating associated with diabetic autonomic neuropathy, and excessive sweating in general. In particular, the following indications can be treated according to the present invention and are associated with dermatology, e.g. eccrine nevus, idiopathic unilateral focal hyperhidrosis, vascular deformities, pretibial myxedema; associated with gynaecology, e.g. postmenopausal hyperhidrosis; iatrogenic, such as associated with medicines, namely methadone or other opiates, cholinergics such as galantamine, SSRIs; associated with infection, e.g. brucellosis, HIV, chronic malaria, TBC, endocarditis; associated with surgery e.g. compensatory hyperhidrosis after sympathectomy; associated with medicines, such diabetes (hyperhidrosis due to neuropathy or hypoglycaemia), endocrine diseases (acromegaly, pheochromocytoma, hyperthyroidism, hypogonadism, insulinoma, heart failure, obesity); associated with neurology, e.g. central or peripheral lesion, Harlequin syndrome, Horner's syndrome, compensatory hyperhidrosis, Ross syndrome, Parkinson's disease, polyneuropathies; associated with oncology, such as carcinoid, lymphoma, with several malignancies; associated with orthopaedics, e.g. hyperhidrosis from amputation stump; associated with psychiatry, e.g. anxiety disorder, psychotropic drugs, social phobia. Non-therapeutic (cosmetic) use of the topical formulation of the present invention includes the topical application of the formulation on the skin of a mammal in individuals experiencing excessive sweating rated as (or at least comparable with the state of) 3 or 4, preferably as 4, in the Hyperhidrosis Disease Severity Scale (HDSS).
- The formulation of the present invention is applied topically on the skin of a mammal. Typical application sites include the face (e.g. forehead, chin, neck and scalp), armpit (axilla), underarms, palms of the hands, soles of the feet, backs of the knees, trunk, and groin. A particularly preferable application site according to the invention is the armpit (axilla).
- The following examples show preferred embodiments of the invention.
- The following examples have been prepared by combining the indicated ingredients using a conventional mixer (e.g. Becomix RW 320). All ingredients are commercially available. Macrogol 20 glycerol monostearate is also known as polyethylene glycol (PEG)-20 glyceryl stearate. Glycerol monostearate 40-55 is also known as glycerol monostearate 40-55% (Type II). Cetostearyl alcohol is a mixture of cetyl and stearyl alcohols.
-
Position Substance g/100 g 1 Macrogol 20 glycerol monostearate 7.00 2 Glycerol monostearate 40-55 4.50 3 Cetostearyl alcohol 8.00 4 Octyldodecanol 8.00 5 Benzyl alcohol 1.00 6 Glycopyrronium bromide 1.00 7 Citric acid, anhydrous 0.32 8 Sodium citrate 0.30 9 Propylene glycol 3.00 10 Purified water 66.88 -
Position Substance g/100 g 1 Macrogol 20 glycerol monostearate 7.00 2 Glycerol monostearate 40-55 4.50 3 Cetostearyl alcohol 8.00 4 Octyldodecanol 8.00 5 Benzyl alcohol 1.00 6 Glycopyrronium bromide 0.50 7 Citric acid, anhydrous 0.32 8 Sodium citrate 0.30 9 Propylene glycol 3.00 10 Purified water 67.38 -
Position Substance g/100 g 1 Macrogol 20 glycerol monostearate 7.00 2 Glycerol monostearate 40-55 4.50 3 Cetostearyl alcohol 8.00 4 Octyldodecanol 8.00 5 Benzyl alcohol 1.00 6 Glycopyrronium bromide 2.00 7 Citric acid, anhydrous 0.32 8 Sodium citrate 0.30 9 Propylene glycol 3.00 10 Purified water 65.88 - All Preparation Examples exhibited a good stability of the O/W emulsions over 36 months during stability testing (stability of emulsion in terms of phase separation and in terms of stability of active pharmaceutical ingredient (API)).
- Formulations according to the present invention were tested in a clinical trial assessing pharmacokinetics, local and systemic tolerability and local efficacy of glycopyrronium bromide (GPB) in a topical formulation in a placebo controlled, double blind study in subjects with severe axillary hyperhidrosis. 517 patients with primary axillary hyperhidrosis were enrolled in the study. According to the present invention only patients suffering from severe hyperhidrosis rated as 3 or 4 in the Hyperhidrosis Disease Severity Scale (HDSS) and at least 50 mg of sweat production over a period of 5 minutes were evaluated.
- The patients received the 1%-GPB-containing cream of Preparation Example 1. During the first 8 weeks (initial phase) the patients applied a predetermined dose of the cream (540 mg cream, corresponding to 4.4 mg glycopyrronium) per axillae 5 times per week. Following the initial phase the frequency of application was reduced to (in average) 3 times per week (maintenance phase). Over a period a 72 weeks the treatment success was maintained with the lower frequency of product administration of the maintenance phase.
- Treatment success is shown by means of reduction in HDSS and gravimetric measurement of absolute sweat reduction. However, other parameters to define success of treatment are also possible, examples include but are not limited to other quality of life measurement tools such as DLQI, HidroQoL, Skindex-16 etc., or other means of objective sweat measurement such as minor tests, size of sweat stains etc.
- The above-mentioned results clearly show that the present invention using a reduced administration regime as defined in the claims is highly effective even in the treatment of severe hyperhidrosis (namely in patients suffering from hyperhidrosis rated as 3 or 4, in particular as 4, in the HDSS).
Claims (10)
- A topical formulation comprising at least one anticholinergic compound for use in treating patients suffering from severe hyperhidrosis, wherein administration of the formulation to the patient comprises:a) an initial phase with a topical administration of a predetermined amount of the formulation 5 to 7 times per week for a total time period of less than six months; followed byb) a maintenance phase with a topical administration of the same amount of the formulation 1 to less than 5 times per week.
- The topical formulation for use according to claim 1 in the form of an emulsion, preferably an oil-in-water emulsion comprisinga) a disperse/inner oil phase;b) a continuous/outer water phase containing the anticholinergic compound; andc) an emulsifier.
- The topical formulation for use according to claim 1 and/or claim 2, wherein the anticholinergic compound is selected from the group of oxybutinin, glycopyrronium (GP) salts, umeclidinium salts, and sofpironium salts, preferably selected from the group consisting of the bromide, the acetate, and the tosylate salts of glycopyrronium (GP), umeclidinium, and sofpironium, respectively.
- The topical formulation for use according to claim 3, wherein the GP salt is a racemic mixture of (3R)-3-[(2S)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide and (3S)-3-[(2R)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide or a racemic mixture of (3R)-3-[(2S)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium tosylate and (3S)-3-[(2R)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium tosylate.
- The topical formulation for use according to claims 3 and/or 4, wherein the GP salt is contained in an amount of 0.05 to 5 wt.%, preferably of 0.1 to 3 wt.%, more preferably of 0.2 to 2 wt.%, and even more preferably of 0.5 to 1.5 wt.%, based on the weight of the total formulation.
- The topical formulation for use according to any one of claims 1 to 5, wherein administration of the formulation to the patient comprises:a) an initial phase with a topical administration of a predetermined amount of the formulation once-daily for a total time period of from two weeks to four months, preferably for a total time period of from three weeks to two months, most preferably four weeks; followed byb) a maintenance phase with a topical administration of the same amount of the formulation two to four times, preferably two to three times, most preferably two times per week.
- The topical formulation for use according to any one of claims 1 to 6, wherein the amount of the formulation per administration is within a range of from 200 to 800 mg, preferably from 400 to 600 mg, per application site.
- The topical formulation for use according to any one of claims 1 to 10, wherein the hyperhidrosis to be treated is selected from the group consisting of primary and secondary hyperhidrosis, gustatory sweating associated with Frey's syndrome, gustatory sweating associated with diabetic autonomic neuropathy, and excessive sweating, preferably axillary hyperhidrosis.
- Pharmaceutical composition comprising the topical formulation according to any one of claims 1 to 13 and one or more pharmaceutically acceptable excipients.
- Non-therapeutic use of a topical formulation comprising at least one anticholinergic compound, for reducing excessive sweating in subjects, wherein administration of the formulation to the subject comprises:a) an initial phase with a topical administration of a predetermined amount of the formulation 5 to 7 times per week for a total time period of less than six months; followed byb) a maintenance phase with a topical administration of the same amount of the formulation 1 to less than 5 times per week.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22168549.8A EP4260852A1 (en) | 2022-04-14 | 2022-04-14 | Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating |
PCT/EP2023/059763 WO2023198876A1 (en) | 2022-04-14 | 2023-04-14 | Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating |
EP23715892.8A EP4333831B1 (en) | 2022-04-14 | 2023-04-14 | Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22168549.8A EP4260852A1 (en) | 2022-04-14 | 2022-04-14 | Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4260852A1 true EP4260852A1 (en) | 2023-10-18 |
Family
ID=81585088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22168549.8A Withdrawn EP4260852A1 (en) | 2022-04-14 | 2022-04-14 | Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP4260852A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006069998A2 (en) | 2004-12-27 | 2006-07-06 | Beiersdorf Ag | Glycopyrrolate in cosmetic preparations |
WO2014134510A1 (en) | 2013-02-28 | 2014-09-04 | Dermira, Inc. | Glycopyrrolate salts |
WO2014144075A1 (en) | 2013-03-15 | 2014-09-18 | Bodor Laboratories, Inc. | Anticholinergic glycopyrrolate esters for the treatment of hyperhidrosis |
WO2020020879A1 (en) | 2018-07-24 | 2020-01-30 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Topical emulsion of an anticholinergic compound |
WO2020208063A1 (en) | 2019-04-10 | 2020-10-15 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | System for dermal application of a pharmaceutical and/or cosmetic composition |
-
2022
- 2022-04-14 EP EP22168549.8A patent/EP4260852A1/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006069998A2 (en) | 2004-12-27 | 2006-07-06 | Beiersdorf Ag | Glycopyrrolate in cosmetic preparations |
WO2014134510A1 (en) | 2013-02-28 | 2014-09-04 | Dermira, Inc. | Glycopyrrolate salts |
WO2014144075A1 (en) | 2013-03-15 | 2014-09-18 | Bodor Laboratories, Inc. | Anticholinergic glycopyrrolate esters for the treatment of hyperhidrosis |
WO2020020879A1 (en) | 2018-07-24 | 2020-01-30 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Topical emulsion of an anticholinergic compound |
US20210290536A1 (en) * | 2018-07-24 | 2021-09-23 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Topical emulsion of an anticholinergic compound |
WO2020208063A1 (en) | 2019-04-10 | 2020-10-15 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | System for dermal application of a pharmaceutical and/or cosmetic composition |
Non-Patent Citations (4)
Title |
---|
ABELS C. ET AL: "A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial*", BRITISH JOURNAL OF DERMATOLOGY, vol. 185, no. 2, 2 March 2021 (2021-03-02), Hoboken, USA, pages 315 - 322, XP055958742, ISSN: 0007-0963, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/bjd.19810> DOI: 10.1111/bjd.19810 * |
GLASER DEE ANNA ET AL: "A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis", AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, vol. 20, no. 4, 20 May 2019 (2019-05-20), US, pages 593 - 604, XP055958770, ISSN: 1175-0561, Retrieved from the Internet <URL:http://link.springer.com/article/10.1007/s40257-019-00446-6/fulltext.html> DOI: 10.1007/s40257-019-00446-6 * |
HAIDER ASOLISH N: "Focal hyperhidrosis: diagnosis and management", CMAJ, vol. 172, 2005, pages 69 - 75 |
SOLISH NBERTUCCI VDANSEREAU AHONG HCLYNDE CLUPIN M ET AL.: "A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee", DERMATOL SURG, vol. 33, no. 8, 2007, pages 908 - 23, XP055771983, DOI: 10.1111/j.1524-4725.2007.33192.x |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210290536A1 (en) | Topical emulsion of an anticholinergic compound | |
US9138480B2 (en) | Compositions and methods for stimulating hair growth | |
KR100950524B1 (en) | Topical glycopyrrolate product | |
US8679524B2 (en) | Method of topically applying glycopyrrolate solution using absorbent pad to reduce sweating | |
JP2002255725A (en) | Treatment of skin | |
EP4333831B1 (en) | Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating | |
EP4260852A1 (en) | Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating | |
US11191713B2 (en) | Oil in water emulsion | |
US20240148647A1 (en) | An eflornithine composition for inhibiting hair growth | |
US11833238B2 (en) | Topical testosterone (T) for promoting hair growth-containing formulations | |
RU2781009C2 (en) | Oil-in-water emulsion | |
BR112020000379B1 (en) | OIL IN WATER EMULSION | |
EP3569221A1 (en) | Aqueous formulations comprising ipratropium for topical treatment of hyperhidrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20240419 |